https://www.selleckchem.com/pr....oducts/ipilimumab.ht
Ninety-three patients (9.6%) had major complications. The 2-year overall survival rate was 32.7% in the group with major complications and 50.3% in the group with no major complications. Patients with major complications had a significantly poorer prognosis than those without major complications (hazard ratio 1.62; 95% confidence interval 1.21-2.18; .01). Male, rectal tumor, and open surgery were identified to be risk factors for major complications. Postoperative complications after primary tumor resection was associated with de
إعجاب
علق
شارك
